Apostolia M. Tsimberidou, Daniel Catovsky, Ellen Schlette, Susan O'Brien, William G. Wierda, Hagop Kantarjian, Guillermo Garcia-Manero, Sijin Wen, Kim-Anh Do, Susan Lerner and Michael J. Keating Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone Cancer 107
Version of Record online: 12 MAY 2006 | DOI: 10.1002/cncr.21931
Characteristics and clinical outcomes in 70 sequential patients with splenic marginal zone lymphoma/marginal zone lymphoma (SMZL) were reviewed. Treatments with rituximab resulted in higher rates of response, survival, and failure-free survival compared with chemotherapy. Rituximab alone resulted in disappearance of splenomegaly in 92% of patients and normalization of absolute lymphocyte counts. Rituximab should be the treatment of choice, at least in older patients with SMZL who have comorbid diseases.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field